semaglutide/cagrilintide blend cagrilintide semaglutide Cagrilintide + Semaglutide 10mg Sema/Cag Blend - 10mg Vial

Understanding dose-response curves prevents under-dosing (inadequate receptor engagement) and over-dosing (wasteful without additional benefit, potentially increasing side effects)

The REDEFINE clinical trial program has established that: Cagrilintide 2.4 mg + Semaglutide 2.4 mg weekly produces superior weight loss compared to either agent alone The combination achieved 22.7% mean weight reduction at 68 weeks Side effect profiles were manageable with proper dose escalation The amylin + GLP-1 agonist combination demonstrated synergistic effects This validated combination demonstrates that pairing cagrilintide with incretin-based therapies can work effectively

BPC-157 accelerates this process, but it does not change its fundamental biology

Waiting for 3-4 more weeks to see a difference